|   LifeSciVC

A Billion Here, A Billion There: The Cost Of Making A Drug Revisited

By Bruce Booth, DPhil, Partner

The cost of making a new drug has grown to nearly $2.6B, according to the latest and greatest from Tufts Center for the Study of Drug Development (here).  That’s a big and almost unfathomable number.  Critics immediately pounced on it, calling anyone who believed it a flatlander (here), and suggesting that the cost, with failures, was closer to $150M.  Tufts’ number appears incredulous, but the critics paltry number even more so. Read more.


  |   Press Release

Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology

Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment round with $15 million in financing led by Atlas Venture and Novartis. Read more.


  |   LifeSciVC

The Biotech Cross-Over Phenom: Biomarker Of Quality?

By Bruce Booth, DPhil, Partner

As one of big drivers behind the recent IPO window, cross-over investing into private biotech companies by both mutual fund and hedge fund investors has become increasingly commonplace over the past couple years. Read more.


  |   LifeSciVC

Acquisitions As The Silent Partner In Biotech Liquidity: IPO vs M&A Exit Paths

By Bruce Booth, DPhil, Partner

With the biotech IPO window still open for business, and valuations of the recent classes of 2013 and 2014 remaining robust, all eyes have been focused on this part of the value chain. Read more.


  |   In the News

Atlas Venture’s Quartet aims to harness the immune system to make painkillers

While one of the hottest areas of cancer drug development is based on an approach that uses the body’s immune system, a handful of investors are making a $17 million bet on a Cambridge biotech aiming to take a similar approach to pain management. Read more.